NanoVibronix Advances Efforts to Achieve NHS Approval
April 05 2022 - 8:30AM
Business Wire
UroShield Receives Positive Guidance from
NHS
NanoVibronix, Inc. (NASDAQ: NAOV), a medical device
company that produces the UroShield® and PainShield® Surface
Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today
announced that it has received the publication of Guidance from the
National Institute for Health and Care Excellence (NICE) with
recommendations of the company’s UroShield device.
The Guidance states that UroShield has the potential to provide
significant patient and healthcare system benefits in preventing
catheter associated urinary tract infections (UTIs) with further
UK-based research recommended to confirm the positive results shown
for people with long-term catheters and also to determine whether
people with short-term catheters would benefit from using
UroShield, particularly if they are considered at high risk of
infection or have regular catheter blockages.
Encouragingly, NICE also reported that their cost analyses
suggest UroShield may be cost saving in hospital and in people with
repeated UTIs or catheter blockages in community care, and they
recommend the expansion of use by NHS patients so that further real
world evidence can be collected.
Publication by NICE of its recommendation for UroShield is an
important step towards identifying the specific research required
to achieve NHS approval for use by all of its patients at risk of
catheter associated urinary tract infections and blockages.
NanoVibronix is already engaged with the NICE team who are working
with funding bodies to ensure they are aware of the priority of
this further research.
About NanoVibronix, Inc.
NanoVibronix, Inc. (Nasdaq: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology.
The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical
applications, including for disruption of biofilms and bacterial
colonization, as well as for pain relief. The Company’s primary
products include PainShield® and UroShield®, which are portable
devices suitable for administration at home without assistance of
medical professionals. Additional information about NanoVibronix is
available at www.nanovibronix.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) the geographic, social and
economic impact of COVID-19 on the Company’s ability to conduct its
business and raise capital in the future when needed, (ii) market
acceptance of our existing and new products or lengthy product
delays in key markets; (iii) negative or unreliable clinical trial
results; (iv) inability to secure regulatory approvals for the sale
of our products; (v) intense competition in the medical device
industry from much larger, multinational companies; (vi) product
liability claims; (vii) product malfunctions; (viii) our limited
manufacturing capabilities and reliance on subcontractor
assistance; (ix) insufficient or inadequate reimbursements by
governmental and/or other third party payers for our products; (x)
our ability to successfully obtain and maintain intellectual
property protection covering our products; (xi) legislative or
regulatory reform impacting the healthcare system in the U.S. or in
foreign jurisdictions; (xii) our reliance on single suppliers for
certain product components, (xiii) the need to raise additional
capital to meet our future business requirements and obligations,
given the fact that such capital may not be available, or may be
costly, dilutive or difficult to obtain; (xiv) our conducting
business in foreign jurisdictions exposing us to additional
challenges, such as foreign currency exchange rate fluctuations,
logistical and communications challenges, the burden and cost of
compliance with foreign laws, and political and/or economic
instabilities in specific jurisdictions; and (xv) market and other
conditions. More detailed information about the Company and the
risk factors that may affect the realization of forward looking
statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at: http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events, or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220405005386/en/
Investor Contacts: Brett Maas, Managing Principal, Hayden
IR, LLC brett@haydenir.com (646) 536-7331
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Apr 2023 to Apr 2024